Optimized skin penetration

of calcipotriene (Cal) and betamethasone dipropionate (BDP) with PADTM Technology makes the celebration possible1

cal and bdp

Watch the video below to see how PAD™ Technology maximizes the absorption and effect of Cal and BDP1

Cal adds to the anti-inflammatory effect of BDP to reduce the characteristic scaling of psoriasis and restore epidermal barrier function2-6

The complementary activity of Cal + BDP causes a reduction in the characteristic scaling of psoriatic lesions and restores epidermal barrier function3


a vitamin D analogue

Adds to the anti-inflammatory effect of BDP by:

  • Mediating psoriasis-specific immune-modulating activity
  • Increases keratinocyte differentiation
  • Inhibits epidermal hyperproliferation


Betamethasone dipropionate,
a high-potency corticosteroid

Anti-inflammatory effects resulting in decreased expression of key cytokines:

  • TNF-α
  • IL-23
  • IL-17A/F

BDP: betamethasone dipropionate; Cal: calcipotriene; IL: interleukin; TNF: tumor necrosis factor.

PAD™ Technology augments the complementary effects of Cal and BDP by optimizing absorption and minimizing surfactants1,3

PAD™ Technology stabilizes Cal and BDP droplets chemically and physically7

PAD™ Technology augments the complementary effects of Cal and BDP by optimizing absorption and minimizing surfactants

Fully solubilized, active Cal and BDP are delivered to the stratum corneum7

PAD™ Technology augments the complementary effects of Cal and BDP by optimizing absorption and minimizing surfactants

Important safety information

INDICATION: Wynzora® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. ADVERSE EVENTS: In the pivotal trial, the most common adverse reactions (≥1%) were: upper respiratory infection (7%), headache (2%), and application site infection (1%). WARNINGS AND PRECAUTIONS: For topical use only. Patients should not use more than 100g of Wynzora® Cream per week. Do not use near or in the mouth, eyes or intravaginally. Avoid using Wynzora® Cream on the face, groin or armpits, or if they have atrophy at the treatment site. Discontinue use once plaque psoriasis is under control or at 8 weeks. Do not use Wynzora® Cream with occlusive dressings. Hypercalcemia and hypercalciuria have been observed with topical use of calcipotriene. Wynzora® Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment. Wynzora® Cream may cause vision problems, including increasing the risk of cataracts and glaucoma. It is not known if Wynzora® Cream may harm your unborn baby. Breastfeeding women should not apply Wynzora® Cream directly to the nipple or areola; it is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Praestegaard M, Steele F, Crutchley N. Polyaphron dispersion technology, a novel topical formulation and delivery system combining drug penetration, local tolerability and convenience of application. Dermatol Ther (Heidelb). 2022;12(10):2217-2231. doi:10.1007/s13555-022-00794-y 2. Satake K, Amano T, Okamoto T. Calcipotriol and betamethasone dipropionate synergistically enhances the balance between regulatory and proinflammatory T cells in a murine psoriasis model. Sci Rep. 2019;9(1):16322. doi:10.1038/s41598-019-52892-1 3. Lovato P, Norsgaard H, Tokura Y, Røpke MA. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81(3):153-164. doi:10.1016/j.jdermsci.2015.12.009 4. Segaert S, Shear NH, Chiricozzi A, et al. Optimizing anti-inflammatory and immunomodulatory effects of corticosteroid and vitamin D analogue fixed-dose combination therapy. Dermatol Ther (Heidelb). 2017;7(3):265-279. doi:10.1007/s13555-017-0196-z 5. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-255. doi:10.1146/annurev-immunol-032713-120225 6. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel, targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. doi:10.1016/j.jaci.2017.07.004 7. Crutchley N, Georgiou M, Praestegaard M, Steele F. PAD Technology™-based CAL/BDP cream demonstrates superior human skin flux properties compared to topical suspension/gel. Poster presented at: The Fall Clinical Dermatology Conference; October 20-23, 2023; Las Vegas, Nevada.

pink close icon

Watch how PADTM Technology optimizes absorption of Cal and BDP3

Play button for Wynzora and PAD™ Technology mechanism of action video
Wynzora MOA video icon